89 results about "Vesicular stomatitis virus VSV" patented technology

The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and / or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.

The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and / or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.

The invention discloses a neurotoxicity-free recombinant live virus vector rabies vaccine, which is prepared by replacing G protein of vesicular stomatitis virus with G protein of HEP-Flury rabies virus strain or G protein mutant of HEP-Flury rabies virus strain, and saving recombinant virus VSV-HEP-Flury by using a reverse genetic manipulation technology. The recombinant live virus vector rabies vaccine has no neurotoxicity after being inoculated. The method is free of neurotoxicity, high in safety, simple in inoculation procedure, good in immune effect and high in productivity.

The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and / or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.

The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and / or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.

The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and / or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.

The invention relates to the technical field of genetic engineering, and particularly provides a multi-linked quality control product for quality control of a novel coronavirus nucleic acid detection laboratory and a preparation method of the multi-linked quality control product. The multi-linked quality control product is a multi-component composite system and is formed by mixing three substances, namely pseudovirus, target gene RNA (Ribonucleic Acid) molecules and internal standard plasmid DNA (Deoxyribose Nucleic Acid). Wherein the pseudovirus is pseudovirus particles of novel coronavirus ORF1ab gene RNA (Ribonucleic Acid) wrapped by a vesicular stomatitis virus vector and is used for monitoring virus nucleic acid extraction; the target gene RNA molecule is a novel coronavirus N gene RNA molecule and can monitor the reverse transcriptase activity; the internal standard plasmid is plasmid DNA of a human housekeeping gene RPP30, and whether inhibition or failure exists in an amplification link is monitored. According to the method, the whole process of nucleic acid extraction, reverse transcription and amplification is synchronously and hierarchically monitored, the monitoring blind area of a traditional single-component quality control product is solved, and the accuracy and efficiency of laboratory detection quality control are remarkably improved.

The invention provides a rabies virus inactivated vaccine and a preparation method thereof, and belongs to the technical field of biological medicines. The invention provides a rabies virus inactivated vaccine. The rabies virus inactivated vaccine comprises an adjuvant and an inactivated VSV-rabies recombinant virus, the inactivated VSV-rabies recombinant virus is obtained by carrying out inactivation on a VSV-rabies recombinant live virus; the VSV-rabies recombinant live virus is prepared by replacing envelope protein G of vesicular stomatitis virus with G protein of rabies virus. The inactivated rabies virus vaccine is good in safety and high in induced antibody level, the immune effect of the inactivated rabies virus vaccine is equivalent to that of a live virus vector vaccine, and the inactivated rabies virus vaccine has a certain application value in the aspect of preventing and controlling rabies.

The present invention pertains to the provision of a vaccine comprising a first component (K) and a second component (V), wherein the first component (K) comprises a complex in which a cell penetrating peptide, an antigenic domain and a TLR agonist are functionally linked and the second component (V) comprises an oncolytic recombinant vesicular stomatitis virus expressing an antigenic domain. The invention further pertains to the use of the inventive vaccine in the treatment of cancer. The invention also provides a recombinant vesicular stomatitis virus expressing an antigenic domain and its use in cancer vaccines.

The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a gasdermin. The invention is further directed to the use of the recombinant virus in the treatment of cancer and also to methods for producing such viruses.

The invention discloses a recombinant virus vector, a vesicular stomatitis-yellow rice chimeric virus and application of the vesicular stomatitis-yellow rice chimeric virus. The recombinant virus vector is a recombinant vector containing an expression cassette of a vesicular stomatitis-yellow rice chimeric genome; the expression cassette comprises a T7 promoter, a coding sequence of a vesicular stomatitis virus N protein, a coding sequence of a vesicular stomatitis virus P protein, a coding sequence of a vesicular stomatitis virus M protein, a coding sequence of a yellow virus F protein and a coding sequence of a vesicular stomatitis virus L protein which are connected in sequence. The replication-deficient recombinant virus for chimeric expression of the LayV F protein is constructed on the basis of the VSV vector, the safety is good, the immunogenicity is good, a high-titer specific IgG antibody and a neutralizing antibody aiming at LayV can be induced to be generated through intramuscular or subcutaneous injection, a new technical choice is provided for preventing or blocking LayV infection, and the replication-deficient recombinant virus has important use and popularization values.

The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and / or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.

The disclosure provides methods for determining the presence of coronavirus neutralizing antibodies in a sample as well as associated compositions and kits. The methods of the disclosure use recombinant vesicular stomatitis virus (VSV) particles, wherein the VSV glycoprotein (G) is replaced by a coronavirus spike(S) glycoprotein or a fragment or a derivative thereof. In a specific embodiment, the S glycoprotein is derived from Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) and the methods are used for determining the presence of SARS-CoV-2 neutralizing antibodies.

The present invention relates to a mutant polypeptide comprising the amino acid sequence of the ectodomain of glycoprotein G of a vesicular stomatitis virus (VSV) strain, wherein said ectodomain comprises the amino acid sequence as set forth in SEQ ID NO: 2 or a sequence having at least 50% of identity with the amino acid sequence as set forth in SEQ ID NO: 2, with at least one substitution of an amino acid residue selected from the group consisting of: a) any amino acid residue located from position 421 to position 429 and any amino acid residue located from position 17 to position 25 of SEQ ID NO:2; or b) any amino acid residue located from a position equivalent to position 421 to a position equivalent to position 429 of SEQ ID NO: 2 and any amino acid residue located from a position equivalent to position 17 to a position equivalent to position 25 of SEQ ID NO: 2, after optimal global alignment with SEQ ID NO:2.

This document relates to methods and materials for treating cancer. For example, this document provides chimeric vesiculoviruses (e.g., chimeric vesicular stomatitis viruses (VSVs)) and methods for using such chimeric vesiculoviruses as an oncolytic agent (e.g., to treat cancer).

The invention provides an antiviral drug screening marker and application of a microsome triglyceride transfer protein inhibitor in preparation of an antiviral drug, and finds new application of the microsome triglyceride transfer protein inhibitor in antiviral infection for the first time compared with the prior art. Experiments prove that the expression level of the microsome triglyceride transfer protein in the process of infecting cells with vesicular stomatitis virus is remarkably increased, and the microsome triglyceride transfer protein is used as an antiviral drug screening marker. The invention provides a new target spot for the treatment of virus infection, and the lomitapide as a marketed drug has verified safety, can be quickly transformed and applied, and has a wide application prospect. The invention has broad spectrum potential of targeting host factors or being effective to various viruses (such as coronavirus and influenza virus).

The invention relates to the technical field of biological medicine, and discloses a lentiviral vector for specifically targeting a target cell and a construction method and application thereof, the lentiviral vector comprises: (1) an antigen targeting artificial protein receptor, the receptor comprising a target cell surface antigen binding domain and a transmembrane domain; (2) a mutated Moreton vesicular disease virus envelope protein; and (3) an expression cassette, wherein the expression cassette comprises a heterologous transgene. The novel lentiviral vector based on the mutated Moreton vesicular disease virus envelope, provided by the invention, can realize specific infection on target cells in vitro and in vivo, and compared with a vesicular stomatitis virus envelope VSV-G, the lentiviral vector constructed based on mutated Moreton vesicular disease virus envelope protein is better in stability in serum, and has a good application prospect. The efficiency of specifically infecting target cells is higher, and the drug effect in a mouse tumor model is more prominent.

The present application relates to the technical field of genetic engineering, and specifically provides a multi-link quality control product for novel coronavirus nucleic acid detection laboratory quality control and a preparation method thereof. The multi-link quality control product is a multi-component composite system, which is formed by mixing three substances of a pseudo virus, a target gene RNA molecule and an internal standard plasmid DNA. The pseudo virus is a pseudo virus particle of a vesicular stomatitis virus vector wrapping a novel coronavirus ORF1ab gene RNA, which is used for monitoring virus nucleic acid extraction; the target gene RNA molecule is a novel coronavirus N gene RNA molecule, which can monitor reverse transcriptase activity; and the internal standard plasmid is a plasmid DNA of a human source housekeeping gene RPP30, which monitors whether there is inhibition or failure in the amplification link. The present application realizes synchronous layered monitoring of the whole process of nucleic acid extraction, reverse transcription and amplification, solves the monitoring blind area of traditional single-component quality control products, and significantly improves the accuracy and efficiency of laboratory detection quality control.

The disclosure provides methods and materials for treating cancer. Specifically, the disclosure provides a chimeric vesiculovirus comprising: (a) a first genomic fragment of a first vesiculovirus species; and (b) a second genomic fragment of a second vesiculovirus species different from said first vesiculovirus species; wherein the vesiculovirus species comprising vesicular stomatitis viruses (VSVs) and morreton Virus (MorV). Further disclosed are methods of using chimeric vesiculoviruses as oncolytic agents for treating cancer.

The application provides a virus envelope chimeric receptor and related biomaterials and applications thereof, and belongs to the technical field of molecular biology. Specifically disclosed is a virus envelope chimeric receptor, which comprises, in sequence, an antibody or antigen-binding fragment thereof, a hinge region, a transmembrane region and an intracellular region; the hinge region is selected from a hinge region composed of a hinge region of a CD8 molecule and a hinge region of a vesicular stomatitis virus envelope glycoprotein; the transmembrane region of the virus envelope chimeric receptor is selected from a transmembrane region of the vesicular stomatitis virus envelope glycoprotein; and the intracellular region of the virus envelope chimeric receptor is selected from an intracellular region of the vesicular stomatitis virus envelope glycoprotein. The virus envelope chimeric receptor is used for virus targeting, can improve the infection ability of viruses, reduces the infection rate of viruses on non-T cells to less than 5%, provides a safety guarantee for in-vivo CAR-T preparation, and can be used for industrial production.

The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CCL21 protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.

The application discloses a recombinant oncolytic virus rVSV M51R The application of C in hepatitis B liver cancer belongs to the field of biological medicine. The recombinant oncolytic virus is a recombinant attenuated vesicular stomatitis virus carrying an HBV HBcAg gene and having an M-R mutation at the 51st amino acid of the M gene. The recombinant oncolytic virus is proved to have a curative effect in a tumor model, and can be used for preparing a therapeutic vaccine for HBV-positive liver cancer, HBV-positive diffuse large B-cell lymphoma and other HBV-positive tumors.

This invention discloses an antiviral traditional Chinese medicine extract, namely total alkaloids from Sophora flavescens root, which can be used to prepare antiviral drugs. This invention also discloses the application of the antiviral traditional Chinese medicine extract, total alkaloids from Sophora flavescens root, as a viral infection inhibitor and / or in the preparation of drugs for the prevention and / or treatment of viral infectious diseases. It can significantly inhibit the amplification of various viruses, including VSV (vesicular stomatitis virus), EMCV (encephalomyocarditis virus), HSV-1 (herpes simplex virus type I), and H1N1 (influenza A virus), at both the cellular and organismal levels.

The invention provides a mutant VSVG and a targeting carrier, and belongs to the field of carrier delivery. There is provided an envelope glycoprotein of a vesicular stomatitis virus having a first mutation and a second mutation, the first mutation causing the envelope glycoprotein not to mediate complement inactivation; the second mutation weakens the ability of the envelope glycoprotein to be recognized by a receptor. The invention also provides a targeting vector which comprises a first molecule combined with an endocytosis receptor of a target cell and a second molecule which is non-complement-inactivated and is used for promoting a substance carried by the targeting vector to release and enter cytoplasm, and the second molecule promotes endosome escape or lysosome escape of the targeting carrier, and prevents the targeting carrier from being inactivated by the complement.

Lassa fever is a zoonotic viral hemorrhagic disease caused by Lassa virus (LASV), endemic in multiple west African countries where the multimammate rat is a main virus reservoir. The broad geographic range of the rodent host places a large population at risk of serious illness. LASV is also a bioterrorism threat. A LASV vaccine is an unmet need. Applicants advance a vaccine based on a live vesicular stomatitis virus vector for immunizing against the LASV surface glycoprotein. Preclinical evaluation exhibited high efficacy in cynomolgus macaques. The animals developed serum antibodies that could mediate antiviral effector functions including direct neutralization of virus infectivity. This vaccine candidate elicited robust protective immunity in cynomolgus macaques that prevented development of detectable viremia and disease for at least 1 year after vaccination. These protective immune response features provide valuable data for comparison to an ongoing phase 1 clinical trial and planned phase 2b / 3 clinical trials.

The invention provides an application of combination of a recombinant oncolytic virus and a monoclonal antibody in preparation of a medicine for treating HBV positive liver cancer. The recombinant oncolytic virus is a recombinant attenuated vesicular stomatitis virus carrying an HBV HBsAg gene and a 4-1BBL gene (wherein the 51st amino acid M in the M gene of the virus is mutated into R). The curative effect of the recombinant oncolytic virus is proved in a tumor model, and the recombinant oncolytic virus can be used for preparing therapeutic vaccines for HBV positive tumors such as HBV positive liver cancer and HBV positive diffuse large B-cell lymphoma.

The invention discloses a nucleoside analogue as shown in a formula I and pharmaceutically acceptable salts thereof, and a preparation method and medical application of the nucleoside analogue and the pharmaceutically acceptable salts thereof, pharmacological experiments prove that the nucleoside analogue and the pharmaceutically acceptable salts thereof have relatively good inhibitory activity on RNA-dependent RNA polymerase, and can inhibit replication of various RNA viruses in the aspect of inhibiting virus replication, so that the nucleoside analogue and the pharmaceutically acceptable salts thereof have good application prospects. Particularly, the compound has relatively good biological activity for treating influenza virus and vesicular stomatitis virus infection. Therefore, the compound provided by the invention has good broad-spectrum antiviral activity, can be used as a broad-spectrum antiviral drug to treat various virus infections, and enriches the inventory of antiviral drugs. The nucleoside analogue has anti-RNA (Ribonucleic Acid) virus activity.

The invention discloses an application of an oxoindole compound in preparation of a drug for resisting vesicular stomatitis virus. The oxoindole compound disclosed by the invention can be used for efficiently inhibiting proliferation of vesicular stomatitis virus (VSV) and has relatively low cytotoxicity. The oxoindole compound provided by the invention has a wide application prospect in preparation of anti-vesicular stomatitis virus drugs and drugs for treating vesicular stomatitis virus infection related diseases. The invention provides a new application of the oxoindole compound in anti-VSV drugs.

The present invention provides sesquiterpenoid derivatives and their application in the preparation of broad-spectrum antiviral drugs. [Solution] The present invention discloses sesquiterpenoid derivatives and their application in the preparation of broad-spectrum antiviral drugs, which stimulate heterogeneous nuclear ribonucleoprotein A2 / B1, activate the TANK-binding kinase 1-interferon regulatory factor 3 cell signal pathway, increase the secretion of endogenous type I interferon, and have inhibitory effects on various viruses. As a broad-spectrum antiviral drug, it can prevent or treat infectious diseases and illnesses caused by various viruses, including new coronavirus, vesicular stomatitis virus VSV-G, human immunodeficiency virus, hepatitis C virus, Japanese encephalitis virus, influenza virus, poliovirus, coxsackievirus, dengue virus, rotavirus, tobacco mosaic virus, measles virus, mumps virus, Ebola virus, Marburg virus, herpes virus and adenovirus. The sesquiterpenoid derivatives can be used as raw materials to prepare oral dosage forms such as tablets, capsules, drip pills, or clinically acceptable pharmaceutical preparations such as inhalants and injections.

The present invention provides a mutant vesicular stomatitis virus G glycoprotein (VSVG) and a targeting vector, relating to the area of ​​vector delivery. The present invention provides an envelope glycoprotein of vesicular stomatitis virus having a first mutation and a second mutation, wherein the first mutation prevents the envelope glycoprotein from mediating complement-mediated inactivation, and the second mutation reduces the envelope glycoprotein's ability to be recognized by a receptor. The present invention further provides a targeting vector comprising a first molecule that binds to an endocytosis receptor of a target cell, and a second molecule that promotes the release of a substance carried on the targeting vector into the cytoplasm rather than causing complement inactivation, wherein the second molecule promotes the occurrence of endosomal or lysosomal escape by the targeting vector and prevents the targeting vector from being inactivated by complement.